Radiopharm Theranostics Limited (RAD.AX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
|
Founder & Executive Chairman | 302.8k | -- | 1956 |
|
Mr. Riccardo Canevari
|
MD, CEO & Director | 1.7M | -- | -- |
|
Dr. Dimitris Voliotis M.D.
|
Chief Medical Officer | 1.17M | -- | 1963 |
|
Mr. Aaron Laurita
|
Chief Financial Officer | -- | -- | -- |
|
Mr. Hitesh Goel
|
Head of Project Management | -- | -- | -- |
|
Mr. Nathan Jong C.A.
|
Joint Company Secretary | -- | -- | -- |
|
Ms. Amritha Sushil
|
Joint Company Secretary | -- | -- | -- |
Radiopharm Theranostics Limited
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
April 14, 2023 at 12:00 AM UTC
20FR12B/A: Form for initial registration of a class of securities of foreign private issuers pursuant to Section 12(b)
March 20, 2023 at 12:00 AM UTC
20FR12B/A: Form for initial registration of a class of securities of foreign private issuers pursuant to Section 12(b)
February 13, 2023 at 12:00 AM UTC
20FR12B: Form for initial registration of a class of securities of foreign private issuers pursuant to Section 12(b)
